NASDAQ:MNTA - Nasdaq -
Looking for long-term buys for your portfolio? Take a look at these 3 top pharmaceutical stocks.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (...
The Trigger That Turned Momenta Pharmaceuticals Inc (NASDAQ:MNTA) Volatility into a Winner.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc (...
Chesapeake Utilities (NYSE:CPK) is up 1.4% after hours following news that it's moving into the S&P SmallCap 600.
Mentions: CPK
Sector ETF report for PSCH
NEW YORK, NY / ACCESSWIRE / September 20, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. Visit our website to learn more about your rights and participate in an action:
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, NY / ACCESSWIRE / September 5, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. To learn more about your legal rights and options, visit:
As Covid shut down large swaths of the non-digital economy, investors dumped stocks whose sales suffered most directly. But now the market seems willing to look ahead to these businesses’ revivals.
Hot biotech stock Immunovant on Wednesday priced its secondary offering of 5.27 million shares at $33 per share, as IMVT stock trades near record highs.
NEW YORK, NY / ACCESSWIRE / September 1, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Varian Medical Systems, Inc. (NYSE:VAR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Siemens Healthineers AG for $177.50 per share. To learn more about your legal rights and options, visit:
Sector ETF report for PSCH
NEW YORK, NY / ACCESSWIRE / August 29, 2020 /Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Principia Biopharma Inc. (NASDAQ:PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sanofi for $100 per share. To learn more about your legal rights and options, visit:
Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.
Momenta Pharmaceuticals stock was thrust into the financial headlines and might look tempting, but don't forget that price is king.
Mentions: JNJ
NEW YORK, NY / ACCESSWIRE / August 25, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Under the terms of the merger, Cellular Biomedicine
Low interest rates and suburban refuges from Covid-19 are driving housing starts. Some indirect beneficiaries: the home-improvement chains. But how long will the boom last?
Some of the most promising opportunities are found among pharmaceutical stocks.
A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.
Mentions: JNJ